A part of Watch Media

MedWatchSaturday4 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
Foto: Stine Tidsvilde

Novo Nordisk hopes to retain employees with share gift

All Novo Nordisk employees have been offered 37 restricted stock units, which can be turned into real B shares in Aug. 2026.
  • Novo Nordisk declared world's best place to work in 2022
  • Novo Nordisk meets upgraded guidance, sets new revenue record

For subscribers

Foto: Novo Nordisk / Pr

Novo Nordisk CEO rakes in cash in record year

For subscribers

Lars Fruergaard Jørgensen, CEO at Novo Nordisk | Foto: Stine Bidstrup

Potential blockbuster submitted by Novo Nordisk for European approval

For subscribers

Christophe Bourdon, CEO at Leo Pharma | Foto: Leo Pharma / Pr

Leo Pharma to reuse model from failed acquisition

For subscribers

Foto: ALK / PR

China accepts regulatory filing for ALK allergy tablet

For subscribers

Foto: Eric Piermont

Dupixent becomes ninefold blockbuster

For subscribers

  • Foto: Alk / Pr

    ALK forecasts lower growth in 2023 than strong 2022 result

    The allergy firm thinks 7–11% growth in 2023 is likely after a strong 2022 performance meets an upgraded guidance from the summer.

    For subscribers

  • Foto: Stine Bidstrup/Ritzau Scanpix

    Europe pharma sector risks lagging the world, say drug chiefs

    Chief executives of Novartis, GSK, and Novo Nordisk say healthcare must become an urgent priority in Europe, else the region risks falling behind the rest of the world.

    For subscribers

  • Foto: Mike Blake/Reuters/Ritzau Scanpix

    Eli Lilly raises 2023 expectations

    A new forecasted tax rate for the fiscal year to come means Lilly can upgrade some expectations, reveals the company’s fourth-quarter report.

    For subscribers

  • Lars Fruergaard Jørgensen, CEO of Novo Nordisk | Foto: Stine Bidstrup

    Novo Nordisk CEO says obesity is "obviously a big market"

    Analysts value the future obesity market in the billions of dollars – and though coy about his own expectations, CEO Lars Fruergaard Jørgensen says Novo Nordisk has ”a very, very significant opportunity.”

    For subscribers

  • Foto: Fabian Bimmer/Reuters/Ritzau Scanpix

    Supply issues to continue in 2023, reports Novo Nordisk

    Investing massively into increasing production capacity, Novo Nordisk hopes to increase its drug supply, though 2023 will still see ”periodic supply constraints,” informs Novo CFO Karsten Munk Knudsen.

    For subscribers

  • Viatris's headquaters in Pittsburgh, Pennsylvania, US | Foto: Viatris/PR.

    Novo Nordisk sues Viatris over copycat Wegovy

    A market authorization application from US-based generics maker Viatris for a copy version of obesity treatment Wegovy breaches five of Novo Nordisk’s patents, claims the company in a lawsuit.

    For subscribers

  • Foto: Arnd Wiegmann/Reuters/Ritzau Scanpix

    Novartis beats Kesimpta sales expectations in Q4

    Multiple sclerosis treatment Kesimpta, based on Genmab-developed ofatumumab, has generated more than analysts predicted in Q4’22.

    For subscribers

  • Foto: Andrew Kelly/Reuters/Ritzau Scanpix

    Analyst: Strong Novo Nordisk outlook should satisfy investors

    An analyst has looked over the Danish drugmaker’s annual report, concluding that there are enough elements – including expected 2023 sales growth of up to 19% – for a Novo stock boost.

    For subscribers

  • Foto: Jens Dresling/Ritzau Scanpix

    Studies of Wegovy in higher-than-approved doses begin

    In January, Novo Nordisk initiated two late-stage studies of semaglutide, the substance in both obesity drug Wegovy and diabetes drug Ozempic, in higher doses than currently approved.

    For subscribers

  • Foto: Novo Nordisk

    Rare Disease business comes in slightly below expectations for Novo Nordisk

    Though hemophilia drug Novoseven surprised positively in Q4, Novo’s Rare Disease segment was let down by its treatments for rare endocrine disorders.

    For subscribers

  • Foto: Stine Tidsvilde

    Novo Nordisk meets upgraded guidance, sets new revenue record

    The Danish drugmaker’s top and bottom lines have increased considerably.

    For subscribers

  • Foto: Novo Nordisk / Pr

    Novo Nordisk doubles obesity sales in 2022

    Wegovy and Saxenda set new records in fiscal 2022, during which particularly the former gave a strong performance near the end, exceeding analysts Q4 expectations by millions of dollars.

    For subscribers

  • Foto: Stine Tidsvilde

    Novo Nordisk predicts wide range for 2023 sales growth

    The Danish drugmaker has released its 2023 guidance with a sales growth expectation of 13–19%. (Updated)

    For subscribers

  • Foto: Eric Gaillard

    Pfizer hopes Covid-19 sales will increase in the long run

    Citing existing stockpiles around the world, Pfizer does not think it can increase sales of its two Covid-19 products in 2023 – but this development will reverse in the future.

    For subscribers

  • Foto: Robert Galbraith/Reuters/Ritzau Scanpix

    Amgen takes on Abbvie blockbuster Humira with unusual price plan

    Abbvie’s multibillion-dollar generating anti-inflammatory drug, Humira, is about to face competition for the first time, as Amgen launches an almost identical product using an unconventional strategy.

    For subscribers

  • Foto: Pr/nordea

    Nordea cuts Lundbeck share target week before annual report

    The bank spots a risk of Lundbeck’s 2023 guidance disappointing analysts who have set expectations too high. 

    For subscribers

  • Foto: Fabian Bimmer/Reuters/Ritzau Scanpix

    Analysts await Novo Nordisk's 2023 guidance with high expectations

    The Danish drugmaker publishes its annual report for a concluded fiscal year tomorrow, Wednesday – and as customary, onlookers want to know what’s next for Novo Nordisk.

    For subscribers

  • Anders Hinsby (left), Thomas Kirkegaard Jensen, and Anders Vadsholt | Foto: Anne Bæk/Ritzau Scanpix

    Orphazyme trio founds new firm focused on neurology and rare diseases

    Anders Hinsby, Anders Vadsholt, and Thomas Kirkegaard Jensen – all three key figures from now-defunct biotech company Orphazyme – have established a new company using experiences from the past.

    For subscribers

  • Foto: Novo Nordisk / PR

    Novo Nordisk wins case in US appeals court

    Three pharmaceutical firms, including Novo Nordisk, have won a case in a US appeals court, which agreed that the drugmakers can limit deliveries of federally discounted drugs.

    For subscribers

  • Foto: Issei Kato

    Alzheimer's drug wins priority review in Japan

    Biogen and Eisai ’s Alzheimer’s treatment candidate gains access to faster case processing by authorities in Japan.

    For subscribers

Latest news

  • Top news from MedWatch this week – 3 Feb
  • Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps – 3 Feb
  • China accepts regulatory filing for ALK allergy tablet – 3 Feb
  • Another hurdle overcome in delaying MDR deadline – 3 Feb
  • Dupixent becomes ninefold blockbuster – 3 Feb
  • ALK forecasts lower growth in 2023 than strong 2022 result – 3 Feb
  • Unilabs and Siemens Healthineers enter million-euro strategic partnership – 3 Feb
  • Coloplast launches male catheter featuring new technology – 3 Feb
  • Novo Nordisk hopes to retain employees with share gift – 3 Feb
  • Coloplast's bottom line disappoints in otherwise strong report – 3 Feb
See all

Jobs

  • Medical Advisor (Metabolism)

  • Senior Clinical Project Manager

  • Lead Data Architect

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Commercial Director

  • Application Manager

  • Regulatory Affairs Professional

  • Clinical Operational Associate

  • Supply Chain Manager

  • Experienced Patent Counsel

  • Senior Health Economics and Outcomes Research (HEOR) Manager

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge